The Manufacturers Life Insurance Company decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 59.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 343,220 shares of the biopharmaceutical company’s stock after selling 495,795 shares during the quarter. […]
Sectoral Asset Management Inc. lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 0.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 22,810 shares of the biopharmaceutical company’s stock after purchasing an additional 130 shares during the quarter. Sectoral Asset Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $5,421,000 at […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.57, Briefing.com reports. The business had revenue of $319.29 million during the quarter, compared to analyst estimates of $312.53 million. Alnylam Pharmaceuticals had […]
State Board of Administration of Florida Retirement System lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 1.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 137,032 shares of the biopharmaceutical company’s stock after selling […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) CFO Jeffrey V. Poulton sold 977 shares of the business’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $190,114.43. Following the completion of the transaction, the chief financial officer now owns 11,706 shares […]